UBE2C and ovarian carcinoma: UBE2C was significantly upregulated in ovarian cancer, and downregulation of UBE2C inhibited cell proliferation, promoted cell apoptosis, induced G2/M cycle arrest, and reversed cisplatin resistance in vivo and in vitro experiments [10].